Sugi Predict

Sugi Predict / Compounds / SCHEMBL4125876

SCHEMBL4125876

SCHEMBL4125876

COC(=O)C1(NC(=O)c2ccc(CN3CCOCC3)cc2)CCCCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.58
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ KDM4E B2RXH2 2/20 0.56
▸ RAB9A P51151 4/20 0.56
▸ NPC1 O15118 3/20 0.56
▸ HIF1A Q16665 2/20 0.55
▸ EPAS1 Q99814 2/20 0.55
▸ TSHR P16473 2/20 0.55
▸ CTSL P07711 2/20 0.53
▸ CTSB P07858 2/20 0.53
▸ CTSS P25774 2/20 0.53
▸ CTSK P43235 1/20 0.53
▸ HPGD P15428 1/20 0.52
▸ LMNA P02545 2/20 0.52
▸ TP53 P04637 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ STAT3 P40763 1/20 0.51
▸ CACNA1B Q00975 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4138462 0.86 ALDH1A1 (0.56) KMT2ASMN1; SMN2MAPK1KDM4ERAB9A
SCHEMBL1838271 0.81 CTSL (0.48) CTSLCTSBCTSSCTSKMAPT
SCHEMBL1840694 0.80 NPC1 (0.58) KMT2ASMN1; SMN2MAPK1KDM4ERAB9A
SCHEMBL11928967 0.78 CTSL (0.48) CTSLCTSBCTSSCTSKMAPT
SCHEMBL1840750 0.77 ALDH1A1 (0.53) KMT2ASMN1; SMN2MAPK1KDM4ERAB9A
SCHEMBL11928588 0.77 TACR2 (0.53) KMT2ASMN1; SMN2MAPK1KDM4ERAB9A
SCHEMBL1839899 0.77 CTSL (0.47) KMT2ASMN1; SMN2MAPK1KDM4ERAB9A
SCHEMBL1841933 0.76 CTSL (0.47) CTSLCTSBCTSSCTSKMAPT
SCHEMBL1842872 0.76 HIF1A (0.51) KMT2ASMN1; SMN2MAPK1KDM4ERAB9A
SCHEMBL1840749 0.76 RAB9A (0.49) KMT2ASMN1; SMN2KDM4ERAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957205-B2 Cycloalkane carboxamide derivatives and production process of same SEIKAGAKU CORPORATION (JP) 2015-02-17 — — US disclosed
US-8957205-B2 Cycloalkane carboxamide derivatives and production process of same SEIKAGAKU CORPORATION (JP) 2015-02-17 — — US disclosed
US-8957205-B2 Cycloalkane carboxamide derivatives and production process of same SEIKAGAKU CORPORATION (JP) 2015-02-17 — — US disclosed
US-8829209-B2 Cycloalkylcarbonylamino acid ester derivative and process for producing the same SEIKAGAKU CORPORATION (JP) 2014-09-09 — — US disclosed
US-8829209-B2 Cycloalkylcarbonylamino acid ester derivative and process for producing the same SEIKAGAKU CORPORATION (JP) 2014-09-09 — — US disclosed
US-8829209-B2 Cycloalkylcarbonylamino acid ester derivative and process for producing the same SEIKAGAKU CORPORATION (JP) 2014-09-09 — — US disclosed
US-8785631-B2 Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core SEIKAGAKU CORPORATION (JP) 2014-07-22 — — US disclosed
US-8785631-B2 Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core SEIKAGAKU CORPORATION (JP) 2014-07-22 — — US disclosed
US-8785631-B2 Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core SEIKAGAKU CORPORATION (JP) 2014-07-22 — — US disclosed
CN-101370773-B Cycloalkanecarboxamide derivative and method for producing same SEIKAGAKU KOGYO CO LTD 2014-04-09 — — CN disclosed
US-20090131661-A1 Oxazolone Derivatives SEIKAGAKU CORPORATION (JP) 2009-05-21 — — US disclosed
US-20090111983-A1 Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same SEIKAGAKU CORPORATION (JP) 2009-04-30 — — US disclosed
US-20090111983-A1 Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same SEIKAGAKU CORPORATION (JP) 2009-04-30 — — US disclosed
US-20090111983-A1 Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same SEIKAGAKU CORPORATION (JP) 2009-04-30 — — US disclosed
EP-2036920-A1 CYCLOALKYLCARBONYLAMINO ACID ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME SEIKAGAKU CORPORATION (JP) 2009-03-18 — — EP disclosed
EP-1975162-A1 OXAZOLONE DERIVATIVE SEIKAGAKU CORPORATION (JP) 2008-10-01 — — EP disclosed
EP-1975162-A1 OXAZOLONE DERIVATIVE SEIKAGAKU CORPORATION (JP) 2008-10-01 — — EP disclosed
EP-1972636-A1 CYCLOALKYLCARBONYLAMINO ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME SEIKAGAKU CORPORATION (JP) 2008-09-24 — — EP disclosed
EP-1972615-A1 CYCLOALKANECARBOXAMIDE DERIVATIVE AND METHOD FOR PRODUCING SAME SEIKAGAKU CORPORATION (JP) 2008-09-24 — — EP disclosed
EP-1972615-A1 CYCLOALKANECARBOXAMIDE DERIVATIVE AND METHOD FOR PRODUCING SAME SEIKAGAKU CORPORATION (JP) 2008-09-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131661-A1 Oxazolone Derivatives CTSK, CTSZ, CTSV KMT2A 4160/4885SMN1; SMN2 3923/4885MAPK1 1705/4885
US-20090111983-A1 Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same CTSK, CTSS, CTSV KMT2A 2173/4885SMN1; SMN2 4647/4885MAPK1 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.